Table 2 Details of the six patients during the therapy
From: Effect of neoadjuvant iodine-125 brachytherapy upon resection of glioma
No. of Patient | Sex | Age | KPS | Symptoms | Previous therapy | No. of 125I seeds implantation | PD | Anatomical location | Grade of gliomas | Subsequent surgery | KPS (last follow up) | Survival time (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Female | 24 | 80 | Headache, vision decline, seizures | NO | 80 | 140 | Frontal (large volume) | WHO IV | Total gross resection | 100 | 51 |
2 | Female | 52 | 90 | Dizziness, seizures | Surgical resection + EBRT + Temozolomide | 50 | 90 | Frontal (eloquent area) | WHO II | Total gross resection | 0 | 34 |
3 | Male | 41 | 90 | Myodynamia decline, seizures | Bevacizumab | 53 | 130 | Parietal (bihemispheric diffusion) | WHO IV | Total gross resection | 0 | 40 |
4 | Male | 46 | 80 | Language disorders, seizures | NO | 26 | 90 | Left hippocampus | WHO I-II | Total gross resection | 80 | 31 |
5 | Male | 22 | 90 | Headache, seizures | NO | 21 | 110 | Frontal (large volume) | WHO II | Total gross resection | 100 | 52 |
6 | Male | 65 | 80 | Headache, vomit, Language disorders, seizures | NO | 100 | 110 | Frontal (eloquent area) | WHO III | Total gross resection | 50 | 33 |